Reversible Cathepsin B Inhibitor Lead Series

Cathepsin B is an abundant and ubiquitously expressed cysteine peptidase involved in many pathological processes, such as inflammation, parasite infection and cancer. To date, most cathepsin B inhibitors are short peptides or small molecules that bind covalently to the enzyme, which is a generally unfavoured feature for drugs. A novel lead series of non-covalent cathepsin B inhibitors has been identified and characterized. Ease of synthesis and favourable properties like good solubility will allow further development and optimization for preclinical testing on a short timescale. Activity, selectivity, cytotoxicity and solubility data has been compiled for a series of about 50 compounds and an SAR has been established. Next steps will involve in vivo testing and further optimization of the lead series.

Further Information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors